×
About 1,268 results

ALLMedicine™ Anaplastic Astrocytoma Center

Research & Reviews  374 results

Global survival trends for brain tumors, by histology: analysis of individual records f...
https://doi.org/10.1093/neuonc/noac217
Neuro-oncology Girardi F, Matz M et. al.

Nov 11th, 2022 - Survival is a key metric of the effectiveness of a health system in managing cancer. We set out to provide a comprehensive examination of worldwide variation and trends in survival from brain tumors in adults, by histology. We analyzed individual ...

Temozolomide Chronotherapy for High Grade Glioma
https://clinicaltrials.gov/ct2/show/NCT02781792

Oct 10th, 2022 - Temozolomide (TMZ) is the chemotherapy drug approved by the FDA to increase survival in glioblastoma (GBM) patients beyond surgical resection and radiation therapy alone. Give its activity in astrocytomas, TMZ is commonly used in grade III anaplas...

MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
https://clinicaltrials.gov/ct2/show/NCT03896568

Aug 15th, 2022 - PRIMARY OBJECTIVES: I. To determine the maximal tolerated dose (MTD) of allogeneic bone marrow-derived human mesenchymal stem cells (BM-hMSCs) loaded with the oncolytic adenovirus DNX-2401 (BM-hMSCs-DNX2401) administered by intra-arterial injectio...

Astrocytoma Treatment & Management
http://emedicine.medscape.com/article/283453-treatment

Aug 15th, 2022 - Approach Considerations Treatment options in astrocytomas include operative intervention and the use of chemotherapy and radiation therapy. Treatment decisions are generally best made by a team approach, including input from the involved neurosurg...

Comprehensive metabolomics study on the pathogenesis of anaplastic astrocytoma via UPLC...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351860
Medicine Du C, Huang Z et. al.

Aug 11th, 2022 - Anaplastic astrocytoma (AA) is a malignant carcinoma whose pathogenesis remains to be fully elucidated. System biology techniques have been widely used to clarify the mechanism of diseases from a systematic perspective. The present study aimed to ...

see more →

Drugs  17 results see all →

Clinicaltrials.gov  87 results

Temozolomide Chronotherapy for High Grade Glioma
https://clinicaltrials.gov/ct2/show/NCT02781792

Oct 10th, 2022 - Temozolomide (TMZ) is the chemotherapy drug approved by the FDA to increase survival in glioblastoma (GBM) patients beyond surgical resection and radiation therapy alone. Give its activity in astrocytomas, TMZ is commonly used in grade III anaplas...

MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
https://clinicaltrials.gov/ct2/show/NCT03896568

Aug 15th, 2022 - PRIMARY OBJECTIVES: I. To determine the maximal tolerated dose (MTD) of allogeneic bone marrow-derived human mesenchymal stem cells (BM-hMSCs) loaded with the oncolytic adenovirus DNX-2401 (BM-hMSCs-DNX2401) administered by intra-arterial injectio...

Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
https://clinicaltrials.gov/ct2/show/NCT03022578

Aug 10th, 2022 - PRIMARY OBJECTIVES: I. Determine the disease control rate at 6 months in patients with recurrent glioblastoma or isocitrate dehydrogenase (IDH)-wildtype anaplastic astrocytoma treated with Laser Interstitial Thermal Therapy (LITT) at recurrence, f...

WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases
https://clinicaltrials.gov/ct2/show/NCT04197934

Aug 5th, 2022 - PRIMARY OBJECTIVE: I. To determine the maximum tolerated dose (MTD) and/or the recommended phase 2 dose (RP2D) of EGFR/EGFRvIII inhibitor WSD0922-FU (WSD0922-FU) in subjects with recurrent glioblastoma, IDH wildtype (GBM), anaplastic astrocytoma, ...

CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma
https://clinicaltrials.gov/ct2/show/NCT04047303

Jul 8th, 2022 - CC-90010-GBM-001 is a multi-center, open-label study to assess the pharmacokinetics (PK), pharmacodynamics (PD) and CNS penetration of CC-90010 following short-term interval therapy (4 daily doses ) prior to surgery, in subjects with progressive o...

see more →

News  27 results

FDA Approves Pedmark for Prevention of Platinum-Induced Ototoxicity in Pediatric Solid Tumors
https://www.onclive.com/view/fda-approves-pedmark-for-prevention-of-platinum-induced-ototoxicity-in-pediatric-solid-tumors

Sep 20th, 2022 - The FDA has approved sodium thiosulfate (Pedmark) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients aged 1 month and older with localized, nonmetastatic solid tumors.1 The efficacy of the product was examined in pe...

Temozolomide Plus Nivolumab Shows Efficacy in Previously Treated ES-SCLC
https://www.onclive.com/view/temozolomide-plus-nivolumab-shows-efficacy-in-previously-treated-es-sclc

Aug 8th, 2022 - Temozolomide (Temodar) in combination with nivolumab (Opdivo) induced a promising overall response rates (ORR) in patients who previously received chemotherapy for extensive-stage small cell lung cancer (ES-SCLC), according to findings from a phas...

Targeted Combo Notches Rare Success in Glioblastoma
https://www.onclive.com/view/targeted-combo-notches-rare-success-in-glioblastoma

Mar 30th, 2022 - For more than 20 years, investigators have tried numerous targeted therapy strategies against glioblastoma (GBM) that have fallen frustratingly short in establishing clinical benefit.1 That changed in November 2021 when an international team of in...

Brain Tumors Exact Higher Mortality Toll in Men Than Women
https://www.medscape.com/viewarticle/968594

Feb 15th, 2022 - New research shows that men in their 20s and 30s have worse survival from many different types of brain tumors than women of the same age. And, researchers say, it’s not exactly clear why. Differences in treatment may mediate some of the associati...

Carboxyamidotriazole Orotate Shows Promising Activity in Brain Cancers
https://www.onclive.com/view/carboxyamidotriazole-orotate-shows-promising-activity-in-brain-cancers

Oct 6th, 2021 - Elena Pentsova, MD Carboxyamidotriazole orotate (CTO) in combination with temozolomide (Temodar), with or without radiotherapy, produced positive safety and efficacy results in a phase Ib study of patients with glioblastoma (GBM) or anaplastic gl...

see more →

Patient Education  2 results see all →